rewirebio.iobenchmarks
Source

Sun et al. 2024, Additional file 1 (Tables S1-S8)

Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318 · Peer-reviewed

DOI: 10.1186/s13059-024-03456-8

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
CelFEER (Sun et al. 2024 benchmark)AUROC (colon cancer vs healthy; random forest on deconvolved cell-type fractions)0.85 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFEER deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFEER (Sun et al. 2024 benchmark)AUROC (gastric (stomach) cancer vs healthy; random forest on deconvolved cell-type fractions)0.91 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFEER deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFEER (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.87 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFEER deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFEER (Sun et al. 2024 benchmark)AUROC (lung adenocarcinoma vs healthy; random forest on deconvolved cell-type fractions)0.80 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFEER deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFEER (Sun et al. 2024 benchmark)AUROC (lung squamous cell carcinoma vs healthy; random forest on deconvolved cell-type fractions)0.78 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFEER deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFEER (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.96 unitlessPlasma cfDNA WGBS, 24 liver cancer patients and 32 healthy individuals (EGAD00001000856)CelFEER deconvolution, disease detection AUC (liver cancer WGBS)
CelFiE (Sun et al. 2024 benchmark)AUROC (colon cancer vs healthy; random forest on deconvolved cell-type fractions)0.91 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFiE deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFiE (Sun et al. 2024 benchmark)AUROC (gastric (stomach) cancer vs healthy; random forest on deconvolved cell-type fractions)0.93 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFiE deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFiE (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.82 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFiE deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFiE (Sun et al. 2024 benchmark)AUROC (lung adenocarcinoma vs healthy; random forest on deconvolved cell-type fractions)0.83 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFiE deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFiE (Sun et al. 2024 benchmark)AUROC (lung squamous cell carcinoma vs healthy; random forest on deconvolved cell-type fractions)0.83 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)CelFiE deconvolution, disease detection AUC (cfMethyl-Seq cohort)
CelFiE (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.93 unitlessPlasma cfDNA WGBS, 24 liver cancer patients and 32 healthy individuals (EGAD00001000856)CelFiE deconvolution, disease detection AUC (liver cancer WGBS)
cfNOMe (Sun et al. 2024 benchmark)AUROC (colon cancer vs healthy; random forest on deconvolved cell-type fractions)0.82 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)cfNOMe deconvolution, disease detection AUC (cfMethyl-Seq cohort)
cfNOMe (Sun et al. 2024 benchmark)AUROC (gastric (stomach) cancer vs healthy; random forest on deconvolved cell-type fractions)0.87 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)cfNOMe deconvolution, disease detection AUC (cfMethyl-Seq cohort)
cfNOMe (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.87 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)cfNOMe deconvolution, disease detection AUC (cfMethyl-Seq cohort)
cfNOMe (Sun et al. 2024 benchmark)AUROC (lung adenocarcinoma vs healthy; random forest on deconvolved cell-type fractions)0.85 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)cfNOMe deconvolution, disease detection AUC (cfMethyl-Seq cohort)
cfNOMe (Sun et al. 2024 benchmark)AUROC (lung squamous cell carcinoma vs healthy; random forest on deconvolved cell-type fractions)0.84 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)cfNOMe deconvolution, disease detection AUC (cfMethyl-Seq cohort)
cfNOMe (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.77 unitlessPlasma cfDNA WGBS, 24 liver cancer patients and 32 healthy individuals (EGAD00001000856)cfNOMe deconvolution, disease detection AUC (liver cancer WGBS)
MethAtlas (Sun et al. 2024 benchmark)AUROC (colon cancer vs healthy; random forest on deconvolved cell-type fractions)0.82 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)MethAtlas deconvolution, disease detection AUC (cfMethyl-Seq cohort)
MethAtlas (Sun et al. 2024 benchmark)AUROC (gastric (stomach) cancer vs healthy; random forest on deconvolved cell-type fractions)0.86 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)MethAtlas deconvolution, disease detection AUC (cfMethyl-Seq cohort)
MethAtlas (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.84 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)MethAtlas deconvolution, disease detection AUC (cfMethyl-Seq cohort)
MethAtlas (Sun et al. 2024 benchmark)AUROC (lung adenocarcinoma vs healthy; random forest on deconvolved cell-type fractions)0.77 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)MethAtlas deconvolution, disease detection AUC (cfMethyl-Seq cohort)
MethAtlas (Sun et al. 2024 benchmark)AUROC (lung squamous cell carcinoma vs healthy; random forest on deconvolved cell-type fractions)0.78 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)MethAtlas deconvolution, disease detection AUC (cfMethyl-Seq cohort)
MethAtlas (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.91 unitlessPlasma cfDNA WGBS, 24 liver cancer patients and 32 healthy individuals (EGAD00001000856)MethAtlas deconvolution, disease detection AUC (liver cancer WGBS)
UXM (Sun et al. 2024 benchmark)AUROC (colon cancer vs healthy; random forest on deconvolved cell-type fractions)0.81 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)UXM deconvolution, disease detection AUC (cfMethyl-Seq cohort)
UXM (Sun et al. 2024 benchmark)AUROC (gastric (stomach) cancer vs healthy; random forest on deconvolved cell-type fractions)0.87 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)UXM deconvolution, disease detection AUC (cfMethyl-Seq cohort)
UXM (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.83 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)UXM deconvolution, disease detection AUC (cfMethyl-Seq cohort)
UXM (Sun et al. 2024 benchmark)AUROC (lung adenocarcinoma vs healthy; random forest on deconvolved cell-type fractions)0.78 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)UXM deconvolution, disease detection AUC (cfMethyl-Seq cohort)
UXM (Sun et al. 2024 benchmark)AUROC (lung squamous cell carcinoma vs healthy; random forest on deconvolved cell-type fractions)0.72 unitlessPlasma cfMethyl-Seq, 225 cancer patients and 193 healthy individuals (EGAD00001009003)UXM deconvolution, disease detection AUC (cfMethyl-Seq cohort)
UXM (Sun et al. 2024 benchmark)AUROC (liver cancer vs healthy; random forest on deconvolved cell-type fractions)0.72 unitlessPlasma cfDNA WGBS, 24 liver cancer patients and 32 healthy individuals (EGAD00001000856)UXM deconvolution, disease detection AUC (liver cancer WGBS)

Claims

Statements this source supports, each with where in the source it was checked.

  • CelFEER (Sun et al. 2024 benchmark): facets.method_types: Facets: method types ["conventional_pipeline"] (Sun et al. 2024 Background: deconvolution by non-negative least squares (MethAtlas) and expectation-maximisation (CelFiE) fitting)
  • CelFiE (Sun et al. 2024 benchmark): facets.method_types: Facets: method types ["conventional_pipeline"] (Sun et al. 2024 Background: deconvolution by non-negative least squares (MethAtlas) and expectation-maximisation (CelFiE) fitting)
  • Evidence summary: plasma ctDNA methylation detection workflows: Summary Six bounded sources compare cfDNA methylation methods. None is a prospective screening study and none measures clinical benefit. Jamshidi et al. 2022 (Cancer Cell), by the GRAIL developers, compared prototype cfDNA classifiers on the same CCGA substudy 1 participants at a 98% specificity threshold set post hoc within each set. On the validation set of 464 cancers and 362 non-cancers, analysed double-blinded, the whole-genome bisulfite methylation classifier detected 34% of cancers (95% CI 30% to 39%; 158 of 464), against 33% for variants with white-blood-cell correction, 30% for copy number with that correction, 27% for copy number, 16% for uncorrected variants and 2.6% for clinical risk factors alone; only the gap to the corrected variant classifier was not marked as significant. Among 127 validation cancers detected by all three representative classifiers, a methylation origin classifier developed after unblinding assigned the correct tissue for 75% (95 of 127), against 41% for copy number and 35% for corrected variants, with 'other' counted as correct for six cancer types. These are case-control results from the assay developer, not screening performance. Sun et al. 2024 (Genome Biology), an independent benchmark whose authors did not develop the tools, deconvolved real plasma with five methods and reported the ROC-AUC of a random forest trained on the estimated cell-type fractions; the paper does not state how the random forest was validated, so the AUCs may be in-sample. For 24 liver cancer patients and 32 healthy individuals (WGBS), AUCs were 0.96 (CelFEER), 0.93 (CelFiE), 0.91 (MethAtlas), 0.77 (cfNOMe) and 0.72 (UXM). On cfMethyl-Seq plasma (30 to 67 patients per cancer type, each against the same 193 healthy individuals), AUCs ranged from 0.72 (UXM, lung squamous cell carcinoma) to 0.93 (CelFiE, gastric cancer), and no method was highest for every cancer type. Giuili et al. 2025, a bioRxiv preprint not yet peer reviewed, ran ten reference-based tools inside the authors' DecoNFlow pipeline on in silico mixtures of tumour tissue or cell-line reads in healthy plasma reads. CelFiE had the lowest overall median tumour-fraction limit of detection in each dataset: 0.0070 (WGBS-TT), 0.0100 (RRBS-TT) and 0.0010 (RRBS-CL). CIBERSORT and EpiDISH had overall medians of 0.1000 to 0.2500 on WGBS-TT and RRBS-TT. For five tools the RRBS-CL values disagree between the supplementary table and Figure 4A and are not shown. Nguyen et al. 2023 (eLife), by the developers of the SPOT-MAS assay at Gene Solutions, compared three tissue-of-origin classifiers on combined methylation, fragment-length, copy-number and end-motif features from cancer patients only. In the validation cohort of 239 patients, overall accuracy was 0.53 (random forest), 0.69 (deep neural network) and 0.69 (graph convolutional network); the graph network was trained with the validation samples in its graph. Zeng et al. 2026 (Nature Cancer), by the cfMeDIP-seq developers, compared a cfMeDIP-seq methylation classifier with fragmentomic features of the same reads and their combinations, reporting means over 10 fold models. In cross-validation on 356 cancers and 64 healthy donors, methylation alone reached AUC 0.986 and detected 0.949 of cancers at 99% specificity; on an independent validation set its sensitivity at 99% specificity was 0.633, against 0.766 for methylation combined with fragment ratios. These sensitivities are read on few healthy controls (six or seven per cross-validation fold and 17 in the validation set), so 99% specificity there allows no false positive among them, and Li-Fraumeni syndrome carriers without current cancer count as cancers in the validation sensitivities. The Source Data give the methylation-only validation AUC as 0.694 and the text as 0.674, so that value is not shown. Xu and Feng 2026, a medRxiv preprint not yet peer reviewed, by authors who did not develop CpGPT, fine-tuned the CpGPT methylation foundation model on public targeted bisulfite cfDNA data from 254 gastrointestinal cancers and 46 non-cancer controls and built four classical classifiers themselves. On three train/validation/test splits with test partitions of about 30 samples, mean test AUROC was 0.9904 for CpGPT against 0.9573 (SVM), 0.9420 (elastic net), 0.8460 (gradient boosting) and 0.8408 (random forest); the candidate CpGs were selected using all 300 samples, including the test partitions. Neither study reports performance in a screening population. Tissue-of-origin evidence here comes from two developer studies, one methylation-only classifier scored on already detected cancers and one multimodal workflow, and neither classifies people without cancer. (ctdnameth-20261009-source-sun2024-additional-file-1: Table S7 I4:M4, M8, J9; ctdnameth-20261009-source-sun2024: Methods P30; ctdnameth-20261009-source-giuili2025-supp-table-3: sheet B B3:D4, B7:C7; ctdnameth-20261009-source-nguyen2023-supp-file-1: Table S9 B19:E19; ctdnajam-20261010-source-jamshidi2022: Table 3 validation column and Results, cancer signal origin prediction; ctdnalit-20261011-zeng2026-source-article: Results P28-P33; ctdnalit-20261011-zeng2026-source-source-data-fig4: sheets Fig.4a-Fig.4d; ctdnalit-20261011-cpgpt2026-source-preprint: Table 3; Methods; Results)
  • MethAtlas (Sun et al. 2024 benchmark): facets.method_types: Facets: method types ["conventional_pipeline"] (Sun et al. 2024 Background: deconvolution by non-negative least squares (MethAtlas) and expectation-maximisation (CelFiE) fitting)
  • Relevance of ctdnameth-20261009-protocol-sun2024-cfmethyl-detection-auc to "Select a plasma ctDNA methylation detection workflow": Assessed by Sun et al. 2024 five-cancer detection from deconvolved plasma cfMethyl-Seq (ROC-AUC per cancer type) (ctdnameth-20261009-source-sun2024: Methods P30, P49; Results P20-P21; ctdnameth-20261009-source-sun2024-additional-file-1: Table S7 H3:M3, H5:M9)
  • Relevance of ctdnameth-20261009-protocol-sun2024-hcc-wgbs-detection-auc to "Select a plasma ctDNA methylation detection workflow": Assessed by Sun et al. 2024 liver cancer detection from deconvolved plasma WGBS (ROC-AUC) (ctdnameth-20261009-source-sun2024: Methods P30, P49; Results P20-P21; ctdnameth-20261009-source-sun2024-additional-file-1: Table S7 H3:M4)
  • UXM (Sun et al. 2024 benchmark): facets.method_types: Facets: method types ["conventional_pipeline"] (Sun et al. 2024 Background: deconvolution by non-negative least squares (MethAtlas) and expectation-maximisation (CelFiE) fitting)

Models, benchmarks and other records

Configurations (5)

Protocols (2)

Evaluations (10)

Use cases (1)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

19 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Archive note
Not archived in the batch: the licence (CC BY-NC-ND 4.0) does not permit redistribution beyond non-commercial verbatim copies; the hash pins the bytes read.
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact SHA-256
1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-024-03456-8/MediaObjects/13059_2024_3456_MOESM1_ESM.xlsx
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1186/s13059-024-03456-8
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Licence
CC-BY-NC-ND-4.0
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Media type
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Publication status
peer_reviewed
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-10-09T19:58:22Z
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Source location
Full artifact bytes; per-result locators on each result
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.source_locator

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Url
https://doi.org/10.1186/s13059-024-03456-8
Source metadata
Sun et al. 2024, Additional file 1 (Tables S1-S8)

Original source ↗

No field-specific location recorded

Version: Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
Retrieved: 2026-10-09T19:58:22Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.url

Source artifact SHA-256: 1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

Primary source retrieved and hashed for the plasma ctDNA methylation use-case pass.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ctdnameth-20261009-source-sun2024-additional-file-1

areas
dna-genomes
contexts
clinical_research
url
https://doi.org/10.1186/s13059-024-03456-8
artifact url
https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-024-03456-8/MediaObjects/13059_2024_3456_MOESM1_ESM.xlsx
version
Additional file 1 (13059_2024_3456_MOESM1_ESM.xlsx) of Genome Biology 25:318
retrieved at
2026-10-09T19:58:22Z
artifact sha256
1489ec85628ec60916f2d91faa131fff375436709edb850fee2ef50c860b31b0
doi
10.1186/s13059-024-03456-8
publication status
peer_reviewed
licence
CC-BY-NC-ND-4.0
media type
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
source locator
Full artifact bytes; per-result locators on each result
archive note
Not archived in the batch: the licence (CC BY-NC-ND 4.0) does not permit redistribution beyond non-commercial verbatim copies; the hash pins the bytes read.
Related records

    Suggest a correction